Ritter pharmaceuticals inc (RTTR)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15
Cash flows from operating activities
Net loss

-7,094

-10,133

-16,313

-18,792

-19,561

-16,868

-12,460

-9,824

-8,203

-7,863

-13,237

-14,752

-16,929

-18,384

-13,016

-12,570

-10,529

-8,787

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

6

6

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Amortization of right-of-use assets

106

105

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Depreciation

-

-

-

-

-

-

-

-

5

5

5

5

5

5

4

3

2

1

0

0

0

Stock-based compensation

347

438

447

524

579

645

710

743

813

895

0

0

0

-

-

-

-

-

-

-

-

Stock based compensation

-

-

-

-

-

-

-

-

-

-

-

-

-

1,359

1,504

1,921

2,472

2,894

0

0

0

Settlement of accounts payable

0

-

-

-

-

893

0

0

0

-

0

0

0

-

-

-

-

-

-

-

-

Amortization of discount on available-for-sale debt securities

-

-9

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Unrealized gain on available-for-sale securities

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accrued interest receivable

-17

-53

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses

-265

87

305

-96

265

254

0

0

0

-

0

0

0

-

-62

23

87

132

0

0

0

Other assets

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

389

-2,506

436

1,067

1,492

3,168

278

163

-100

341

-125

289

-493

1,157

2,033

413

1,125

-344

0

0

0

Accrued expenses

-1,502

-1,228

-267

-241

1,669

953

211

-141

-755

-768

-711

-256

696

608

611

-40

-228

231

0

0

0

Lease liabilities

-113

-97

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other liabilities

-

-13

-14

-14

-15

-2

-1

-0

0

1

1

2

13

13

14

11

-0

-1

0

0

0

Net cash used in operating activities

-9,135

-14,516

-16,054

-17,389

-16,162

-13,332

-12,351

-10,139

-9,158

-7,397

0

0

0

-

-

-

-

-

-

-

-

Cash flows provided by investing activities
Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-9,869

-6,828

-5,721

0

0

0

Purchase of property and equipment

-

-

-

-

-

-

-

-

-

-

-

-

-

8

14

25

24

16

0

0

0

Sale of investments in marketable debt securities

-

6,998

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash flows provided by investing activities

-

6,996

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cash flows from financing activities
Proceeds from the issuance of shares from ATM Agreement

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-25

-24

-16

0

0

0

Stock issuance costs of ATM Agreement

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercises of warrants

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from issuance of shares for Aspire equity line

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from exercising of options on common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

15

9

7

7

5

0

0

0

Deferred offering costs

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net cash provided by financing activities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net increase (decrease) in cash and cash equivalents

436

-6,112

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,007

18,966

18,810

0

0

0

Net decrease in cash and cash equivalents

-

-

-

-

-

-

-

-

13,824

15,585

-4,893

-5,356

-8,996

-8,773

-7,792

-8,887

12,113

13,072

0

0

0

Conversion of preferred stock to common stock

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

-

-

-

-

-

-

Supplemental disclosure of cash flow activities:
Cash paid for interest

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

Cash paid for interest

-

-

-

-

-

-

-

-

0

-

-

-

0

-

-

-

-

0

0

0

0

Cash paid for taxes

15

187

0

0

0

-

-

-

0

0

9

18

80

80

72

63

0

0

0

0

0

Supplemental disclosure of non-cash financing activities:
Conversion of preferred stock to common stock

4,382

6,547

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use assets obtained in exchange for lease liabilities

-

198

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities arising from obtaining right-of-use assets

-

100

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Issuance of shares for settlement of accounts payable

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Cumulative preferred stock dividends

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

327

0

0

0

Accretion of discount on Series C preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

63

0

0

0